Treatment results in non-small cell lung cancer (NSCLC) differ from patient to patient. This is due to the different biological nature of the individual tumors, but also to the effect of the surrounding tumor stroma and the general organism of the patient.
Therefore, there is a tendency to find prognostic and predictive markers to better target treatment for individual patients. Not only at the beginning of the treatment, but also during the development of the disease, when NSCLC changes its characteristics.
These potential markers in the field of clinical and molecular parameters are discussed in detail in this article. In this first part possible clinical markers and tyrosine kinase are described.